Blockchain Registration Transaction Record

HeartBeam Advances Cardiac Care with FDA-Cleared 3D ECG Technology

HeartBeam reports 2025 results with FDA-cleared 3D ECG technology, commercial partnerships, and clinical studies advancing portable cardiac monitoring for heart attack detection.

This development matters because it addresses a critical gap in cardiac healthcare: the inability to capture comprehensive ECG data outside clinical settings. Cardiovascular diseases remain the leading cause of death globally, with many heart attacks going undetected until irreversible damage occurs. HeartBeam's technology enables continuous, portable 12-lead ECG monitoring, potentially allowing earlier detection of heart attacks and arrhythmias, reducing treatment delays that currently contribute to poor outcomes. For patients with known cardiac conditions or risk factors, this could mean life-saving early interventions. For healthcare systems, it offers a tool to reduce hospitalizations through better outpatient monitoring. The technology's FDA clearance and clinical validation through partnerships like Mount Sinai suggest it's moving beyond theoretical promise to practical application, potentially democratizing access to sophisticated cardiac diagnostics that were previously confined to hospitals. As remote healthcare expands post-pandemic, such innovations could reshape standard cardiac care protocols.